First reversal agent available for non-coumarin oral anticoagulant

Idarucizumab (Praxbind) rapidly reverses the anticoagulant effect of dabigatran (Pradaxa), and can be used when an urgent procedure is required or there is uncontrolled or life-threatening bleeding.

 Idarucizumab binds to dabigatran approximately 300-fold more potently than dabigatran does to thrombin. | SCIENCE PHOTO LIBRARY
Idarucizumab binds to dabigatran approximately 300-fold more potently than dabigatran does to thrombin. | SCIENCE PHOTO LIBRARY

Idarucizumab is a humanised monoclonal antibody fragment that binds to dabigatran with a high affinity and neutralises its anticoagulant effect. Idarucizumab does not reverse the effects of other anticoagulants.

Rapid effect after intravenous administration

Further information
View Praxbind drug record 
Summary of Product Characteristics
Manufacturer: Boehringer Ingelheim

Idarucizumab should be given at a dose of 5g. It is administered as two consecutive 2.5g intravenous infusions over 5 to 10 minutes each or as a bolus injection.

A second dose can be considered in the following situations:

  • recurrence of clinically relevant bleeding together with prolonged clotting times
  • if potential re-bleeding would be life-threatening and prolonged clotting times are observed
  • patients require a second urgent procedure and have prolonged clotting times.

Interim analysis of the prospective open-label RE-VERSE AD study showed that the reversal effects of idarucizumab were evident within minutes of administration. Reversal was complete and sustained for at least 24 hours in most patients.

Resumption of anticoagulant therapy

Neutralisation of the anticoagulant effect of dabigatran exposes patients to the thrombotic risk of their condition, and resumption of anticoagulant therapy should be considered as soon as appropriate.

Dabigatran can be restarted 24 hours after administration of idarucizumab. Other antithrombotic therapy can be restarted at any time. Re-initiation of antithrombotic therapy of any kind should only occur if the patient is stable with adequate haemostasis.

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

NICE recommends dabigatran as an option in thromboembolism

NICE recommends dabigatran as an option in thromboembolism

NICE has recommended that dabigatran etexilate (Pradaxa)...

Pradaxa now indicated for DVT and PE

Pradaxa now indicated for DVT and PE

Pradaxa (dabigatran) is now licensed for the treatment...

Pradaxa: safety update owing to risk of serious haemorrhage

Pradaxa: safety update owing to risk of serious haemorrhage

The MHRA has issued updated safety advice for the anticoagulant...

NICE approves dabigatran in atrial fibrillation

NICE approves dabigatran in atrial fibrillation

Dabigatran etexilate (Pradaxa) can now be prescribed...

Pradaxa

Pradaxa (dabigatran etexilate) is the first oral direct...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases